- Oral presentation
- Open Access
A bioengineering approach for rational vaccine design towards the Ebola Virus
© Banton et al; licensee BioMed Central Ltd. 2010
- Published: 07 December 2010
- Combinatorial Library
- Cellular Immune Response
- Antigenic Peptide
- Vaccine Efficacy
The Ebolavirus (EBOV) is extremely lethal with mortality rates ranging from twenty-three to ninety percent. No licensed Ebola vaccine exists and classical protocols for vaccine design do not comply. One solution, rational vaccine design (RVD) is based on two parameters: (1.) identification of epitopes, antigenic peptides that mediate the cellular immune system and (2.) exploitation of the immune system’s ability to recognize and remember vaccines.
To assess RVD feasibility, EBOV proteins were computationally analyzed for epitope identification. To evaluate vaccine efficacy, mathematical models for virus dynamics were simulated using MATLAB. Models relied on data from EBOV cultivation in cell-cultures, and were extended with novel equations to consider memory B- and T-cell production.
First, RVD towards the EBOV is feasible. Computer-based protein analysis identified novel EBOV peptides for vaccine design. A key epitope –EAIVNAQPKCNPN…MHNQDG– was extracted from a three-dimensional structure of an EBOV protein bound to human antibody KZ52. Secondly, vaccine efficacy can be assessed using mathematical models. Multiple simulations of the models revealed generally unknown parameters such as the virus’ birth and cellular infection rates. The models also quantified the cellular immune response necessary for vaccine efficacy in an individual; the specifications of what the vaccine must accomplish.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.